Results 91 to 100 of about 1,066 (137)

Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors

Cancer Research, 2022
Background: RTX-240 is an allogeneic cellular therapy genetically engineered to express high copy numbers of trimeric 4-1BBL and IL-15/IL-15Rα fusion proteins on the RBC surface membrane.
O. Hamid, M. Johnson, J. Luke, R. Maziarz, J. Merchan, Emerson E. Lim, S. Patel, G. Kuesters, Iga Sienczylo, G. Gordon, K. Campbell, Kristin Horton, L. Turka, A. Spira   +13 more
semanticscholar   +1 more source

Abstract 5275: The short-term impact of COVID-19 on lung cancer screening participation and adherence

Cancer Research, 2022
Objective: Screening with low-dose CT (LDCT) effectively reduces mortality from lung cancer. Elective imaging procedures, including lung cancer screening (LCS) LDCT exams, were paused during the height of the COVID-19 pandemic at our institution to ...
Yannan Lin, William Hsu, D. Aberle, A. Prosper   +3 more
semanticscholar   +1 more source

Abstract 5232: Next-generation sequencing revealed clonal architecture and faciliated diagnosis of patients with multiple lung tumors: An analysis of 12 cases

Cancer Research, 2022
Diagnosing multiple lung tumors as multiple primary lung cancer (MPLC) or intrapulmonary metastasis (IPM) has important therapeutic implications.
Wenyang Jiang, Wei Wang, Luting Qiu, X. Zou, Zhiqiu Chen, Q. Geng   +5 more
semanticscholar   +1 more source

Abstract LB139: The RNA signature of immune-related genes and distinct spatial distribution of immune cells are closely associated with the treatment outcomes in the malignant melanoma patients receiving immune checkpoint inhibitors

Cancer Research, 2022
Introduction: The immune checkpoint inhibitors (ICIs) against CTLA-4 and PD-1/PD-L1, have improved survival with long-term durable response for advanced malignant melanomas.
Seoree Kim, S. Jo, Sang‐Yeob Kim, Dong-Jun Bae, Jeong-Oh Kim, Jeong Y Shin, Joori Kim, C. Lee, S. Chun, G. Park, J. Kang   +10 more
semanticscholar   +1 more source

Abstract 4118: Brain metastases (BM) and next-generation sequencing (NGS) timing: Real-world (RW) outcomes for patients (pts) with advanced non-small cell lung cancer (aNSCLC) and MET exon 14 skipping mutations (METex14)

Cancer Research, 2022
Background: Treatment (Tx) options for METex14 NSCLC have been limited to chemotherapy (Ctx), immunotherapy (IO), and multikinase inhibitors (MKi) until FDA approvals of selective MET inhibitors (METi) from 2020. BM are a further challenge to treat. We
X. Le, S. Robb, N. Caro, S. Doria, W. Rhodes, Wen-Hsing Wu, Julia Kim, V. Pretre, Fen Ye   +8 more
semanticscholar   +1 more source

Abstract 443: Predictors of mortality in hospitalized African American COVID19 cancer patients

Cancer Research, 2022
Background: Coronavirus disease 2019 (COVID-19) and associated outcomes manifest differently depending on patients’ background and pre-existing conditions. It remains unclear how African Americans with and without cancer have been affected.
S. Challa, L. Chirumamilla, Nader A. Shayegh, Josie Z. Fazzino, A. Laiyemo, philip Oppong-Twene, Z. Sherif, O. Lawal, Daniel Larbi, G. Oskrochi, H. Brim, H. Ashktorab   +11 more
semanticscholar   +1 more source

Virtual Communication and its Negative Impact on the Generation of Creative Ideas

International Journal of Clinical Studies and Medical Case Reports, 2022
During the Covid-19 pandemic, the global scenario changed and the people had to adapt to social isolation, which led to an increase in the utilization of remote technologies in multiple areas.
Júlio César Claudino dos Santos
semanticscholar   +1 more source

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Cancer Research, 2022
Background: KRAS G12C oncogenic mutations occur in ~13% of non-small cell lung cancers (NSCLCs) and up to 4% of other solid tumors. JDQ443 is a selective, covalent, orally bioavailable, investigational KRASG12C inhibitor that irreversibly traps ...
D. Tan, Toshio Shimizu, B. Solomon, R. Heist, M. Schuler, M. D. M. Luken, A. Gazzah, M. Wermke, C. Dooms, H. Loong, N. Steeghs, E. Felip, C. Steuer, E. Van Cutsem, R. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, H. Burks, A. Farago, P. Cassier   +22 more
semanticscholar   +1 more source

Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer

Cancer Research, 2022
Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically, inhibition of CD39 by TTX-030, a first-in-class fully human anti-CD39 antibody, reversed ...
Z. Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Seung-Tae Kim, J. Chao, D. Catenacci, S. Oh, Heloisa P Soares, J. Selfridge, Y. Cha, R. Skeel, Hyung-Don Kim, Anh Tran, Achim K. Moesta, Tracy dela Cruz, A. Singhal, Tom Jahn, F. Dayyani   +17 more
semanticscholar   +1 more source

Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors

Cancer Research, 2022
Background: IL-12 is a key mediator of antitumor immune response. In preclinical models, IT IL-12 mRNA led to IFNγ release and CD8+ T cell-dependent tumor regression and potentiated PD-L1 blockade.
B. Carneiro, D. Zamarin, T. Marron, I. Mehmi, S. P. Patel, V. Subbiah, A. El-Khoueiry, D. Grand, K. Garcia-Reyes, S. Goel, Phillip Martin, Jixin Wang, Yuling Wu, Steve Eck, Benjamin Ridgway, N. Elgeioushi, J. Eyles, N. Durham, A. Azaro, Omidvarborna Hamid   +19 more
semanticscholar   +1 more source